Things You Need to Know About the Kratom Ban in Some States

Kratom in Some States

In all states of the US, which stems from this popularity. Complete legalization seems unlikely, mostly because of the kind of resistance it has to go through.

At the moment, a Kratom ban exists in six states of the United States alone, which does raise a few eyebrows about the substance and its effects.

Kratom’s Dosage

You being a user of Kratom understand the level of effect it has on your body. It uplifts your sensory experience and relaxes your mind in this stressful world. But, what are limits of this experience?

Some experts suggest that Kratom’s consumption in low doses makes it a stimulant. However, its consumption in high quantities could cause it to have an effect similar to an opioid painkiller on your body.

Knowing that different types of Kratoms have varying properties that can induce sedating effects and provide relief from your pain, it shows that officials do not have a proper understanding of Kratom.

Comparison with Thailand

Thailand’s government banned Kratom’s usage on the basis that it will affect the revenue that the country gets from its opium tax. Adopting the same model and rationale, the United States went for a similar policy change. Not only this, but Kratom is the biggest challenge right now for the US’s big pharmaceutical companies, because people find best Kratom to be better than heavy medications.  

With this logic, the ban of Kratom today seems to be gaining more traction. Alabama was the sixth state to ban Kratom. Banning ingredients of Kratom is another approach adopted by many states.

All these developments shape the narrative around the use of Kratom.

Withdrawal Symptoms

The popular discourse for Kratom suggests that it contains qualities that lead to withdrawal symptoms if a person stops consuming it. Now that is true for anything that is used in the long-run and develops into a habit. This argument suggests that Kratom itself is harmless, but when it mixes with Mitragynine, it responds to opioid receptors in your brain. And these are the same receptors that respond to morphine, heroin, and oxycodone.

If you want statistics to support Kratom’s usage, then five million people admit the positive results of Kratom on their body and mind. There are more deaths caused by opioids than by Kratom. Moreover, Kratom helps with opioids addiction.

Kratom does not harm the respiratory system; it does not have an overdose risk. If anything, countries should promote Kratom usage.

States should put their focus on researching about these products, before they declare them illegal. Without research, you might doubt the efficiency of Kratom altogether. The decision to ban a product is never so simple that it should be made without all the facts. This is true for Kratom’s ban as well. People are switching to Kratom to increase their productivity all over the world.

 

 

Alberto Espay

Dr. Espay
  1. Alberto J. Espay, MD, trained in clinical and electrophysiology of Movement Disorders at the Toronto Western Hospital, completing an MSc program in Clinical Epidemiology and Health Care Research and a Dystonia Medical Research Foundation Clinical Research Fellowship (University of Toronto, 2001-2005). He has published over 60 peer-reviewed articles and book chapters, and has authored the books Concise Neurology (Lippincott Williams & Wilkins/Wolters Kluwer Health, 2011), with Dr. Jose Biller; Common Movement Disorders Pitfalls (Cambridge University Press, 2012), with Dr. Anthony Lang; and Practical Neurology Visual Review (Lippincott Williams & Wilkins/Wolters Kluwer Health, 2013 [in press]), with Dr. Jose Biller.

Dr. Espay received the Dean’s Scholar in Clinical Research Award by the University of Cincinnati for three consecutive years (2006-09), the NIH-funded KL2 Research Scholars Mentored Award (2010-12), and the NIH-funded K23 Career Development Award (2011-16). He is Associate Professor and Clinical Research Director of the James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders at the University of Cincinnati and has served as the neuroscience representative to the Institutional Review Board and the Advisory Board of UC Physicians Clinical Trials Organization. He serves as Assistant Editor of Movement Disorders, the official journal of the Movement Disorder Society, Associate Editor of Frontiers in Movement Disorders, and on the Editorial Board of The European Neurological Journal, as well as ad hoc reviewer for over 20 other neurological and medical journals. He has served as faculty for a variety of annual educational courses at the American Academy of Neurology and Movement Disorders Congresses since 2007. He became an honorary member of the Mexican Academy of Neurology in 2008, joined the Best Doctors in America list in 2009, received the Business Courier’s ‘Forty Under 40′ award in 2010, and the Patients’ Choice and Compassionate Alternative Medicine Doctor awards in 2011.

Education

Medical School
Central University of Venezuela – Caracas, Venezuela
Residency
Indiana University – Indianapolis, IN
Fellowship
University of Toronto – Toronto, Ontario
Education
University of Toronto – Toronto, Ontario

 

Board Certifications

American Board of Psychiatry & Neurology

American Academy of Neurology
Indiana Neurological Society
Movement Disorders Society
Canadian Neurological Society
Huntington Study Group
Central Society for Neurological Research
Toronto Western Extended Research Network

Research

As a member of the region’s only academic health system, UC Health, the UC Gardner Neuroscience Institute offers its patients unparalleled access to cutting-edge research, world-class clinical trials, the most advanced technology and the latest innovations in medical treatment and care.

Hope for Tomorrow

The UC Gardner Neuroscience Institute is proud to be:

  • The developer of the first live, attenuated polio vaccine, developed by UC College of Medicine faculty member Albert Sabin, MD, in 1960.
  • The first to receive FDA approval to use the YAG laser to vaporize inoperable brain tumors by John M. Tew, Jr, MD, in 1984.
  • The pioneer of t-PA, tissue plasminogen activator, for the treatment of patients with ischemic stroke, which our faculty studied in 1987.
  • The national coordinating center for StrokeNet – a network of 25 regional stroke centers in the US.
  • A member of the Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT – a national network designed to expand new therapies and increase the efficiency and access to new clinical trials.
  • The developers of the FAST acronym, which has been adopted worldwide for stroke symptoms (Face droops, Arms drift down, Speech slurs, Time to call 9-1-1).
  • Cincinnati’s hub for the Cancer Genome Atlas Research Network, a collaboration between the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) that created a genomic data analysis pipeline for 33 types of cancer.
  • World-renowned prominence in our Epilepsy Center for the testing of new antiepileptic drugs.
  • Founding member of the National Network of Depression Centers (NNDC), a clinical and research consortium organized to advance scientific discovery.

Highlights from 2016

In 2016:

  • 172 of our published articles appeared in peer-reviewed academic journals.
  • 94 clinical trials were offered to neurologic and psychiatric patients.
  • 25 basic (laboratory) scientists created extensive research on the most effective dosage of kratom capsules, seeking cures and facilitating other discoveries and breakthroughs

Click to expand each center to learn more about its research areas and clinical trials opportunities.

The UC Brain Tumor Center is committed to the discovery of new treatments for brain tumors. That commitment embraces basic science research, translational research (the translation of laboratory discoveries into treatments) and clinical trials involving new drugs, treatments, and technologies.

Our clinical research team includes physicians in all neuroscience specialties, neuroimaging specialists, research nurses, and regulatory experts. Our clinical trials explore new CBD Oil therapies for Sleep problems, treatments or procedures for several types of brain tumors and related conditions, including acoustic neuroma, gliomas, glioblastoma multiforme, metastatic brain tumors, and radiation necrosis. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

The UC Comprehensive Stroke is committed to advancing treatments that offer the best possible outcomes for patients. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

The Epilepsy Center has a long history of dedication to clinical and scientific research. As one of the leading international centers in natural CBD treatment  development, drug comparisons, and the design of trials for drug testing, the center has helped bring 13 new treatments to market. The center has developed new methods of epilepsy surgery evaluation, and it has developed new methods for identifying seizures in comatose patients and for studying EEG and fMRI simultaneously to better understand underlying mechanisms of epilepsy. Our scientific experts have made discoveries related to depression and epilepsy, the genetics of epilepsy, seizure-like attacks not related to epilepsy, and cognitive testing that optimizes CBD and Cannabis treatment and that measures the effects of seizures and medications. We have conducted research into the best treatments for pregnant women with epilepsy. Our groundbreaking Stress Management Intervention for Living with Epilepsy (SMILE) uses smartphones in an effort to determine whether stress can precipitate seizures and, if so, whether a reduction in stress can keep seizures from occurring at all.

Our clinical cannabidiol research team includes physicians in all neuroscience specialties, neuroimaging specialists, research nurses, and regulatory experts. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

At the Gardner Center for Parkinson’s Disease and Movement Disorders, a national Morris K. Udall Center for Parkinson’s Disease Research, our physicians combine clinical treatment expertise, medical research, new experimental compounds and proven, established medications to help determine the most effective treatments for Parkinson’s disease and other movement disorders. Supported by a dedicated staff of graduate students, postdoctoral fellows, and technicians, the research team is committed to changing the face of Parkinson’s disease through research and discovery. The team seeks new ways to manage and alleviate symptoms; it seeks new therapies to slow disease progression; and it seeks, above all, to find a cure.

Clinical researchers are exploring different strategies to improve freezing of gait and the effects of strength and balance training on balance and cognitive impairments in people with Parkinson’s disease. Other studies are examining the effect of deep brain stimulation (DBS) surgery on balance and the use of CoEnzyme Q10 as a potential disease-modifying agent for patients with Parkinson’s disease and Huntington’s disease. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Headache and Facial Pain Center

The Headache and Facial Pain Center advances treatments that offer the best outcomes for patients. Some of our recent innovations include:

  • Leading a scientific review on specific food triggers for migraines. Triggers include caffeine, monosodium glutamate (MSG), nitrites and excessive alcohol. Other studies have looked at aspartame’s effects, which can trigger headaches in a small percentage of people.
  • Demonstrating the link between lightning and the onset of headaches and migraines.

Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Memory Disorders Center

The UC Memory Disorders Center is committed to advancing treatments that offer the best possible outcomes for patients with Alzheimer’s disease and other causes of cognitive impairment. Collaboration with our partners within the UC Gardner Neuroscience Institute and the UC College of Medicine has already improved our understanding of cognitive aging. Our research explores the implementation of new diagnostic tests, new medications and natural remedies including kratom , the potential for lifestyle modifications to impact cognitive health and the clinical impact of memory disorders upon quality of life.

The Cognitive Aging Program is part of the UC’s Department of Psychiatry and Behavioral Neuroscience, conducts research studies on strains of kratom  to identify mechanisms associated with age-related cognitive decline and to improve memory function in middle-aged and older adults. Our aim is to prevent or delay progression to dementia. These studies involve interventions using kratom powder that can be implemented through lifestyle modifications such as dietary manipulation and supplementation as well as pharmaceutical agents.

Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Mood Disorders Center

The UC Mood Disorders Center is a national research leader that actively creates the future of personalized medicine. One of our primary goals is to decrease the amount of time between the onset of a mood disorder and successful diagnosis and treatment for the patient. Our research areas include developmental neuroscience, neuroendocrinology, molecular neurobiology research, obesity research, post-traumatic stress disorder, stress neurobiology, and addiction.

Our current research embraces more than two dozen clinical trials and research projects relating to alcohol and nicotine addiction, Alzheimer’s disease/dementia, bipolar mania and depression, major depression, schizophrenia, and schizoaffective disorder. We study brain physiology in people with psychiatric and behavioral disorders, the neurofunctional and neurochemical effects of medications, and the differences in brain function in people with different diagnoses. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Neurobiology Research Center

The UC Neurobiology Research Center promotes basic research aimed at understanding causes of neurological and psychiatric pathologies, identifies novel and innovative strategies to advance treatments and cures, partners with clinicians to generate translational research programs linking the ‘bench’ to the ‘bedside’ and fosters collaborative research among UC Gardner Neuroscience Institute and community partners including Cincinnati Children’s Hospital Medical Center and the Cincinnati VA Medical Center.

Our current research areas include causes and possible treatments for depression, post-traumatic stress disorder, addiction and panic disorder, epilepsy onset and disease susceptibility, assessment of prognosis and treatment of traumatic brain injury, Parkinson’s Disease and other movement disorders, schizophrenia and addictive disorder along with causes and devising new treatments for neuropathic pain.

UC Neurosensory Disorders Center

The Neurosensory Disorders Center is committed to developing clinical and basic science research programs to help us understand, diagnose and treat all types of diseases and disorders of the senses. Some of our current research areas include voice and vocal fold, hearing loss – including genetics, diagnosis and treatment, functional magnetic resonance imaging (fMRI) and the effect of sound on the brain pathways and processing, inner ear disease, sleep apnea and swallowing disorders. Our team is involved in innovative research and clinical trials. With more than $4 million in funded research, our goal is to foster multidisciplinary relationships that advance science and lead to new treatments.

Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Neurotrauma Center

The Neurotrauma Center has a long history of dedication to clinical and scientific research.

Clinicians work with researchers and drug and medical device companies to study developing and newly available technologies that seek to maximize outcomes following traumatic injury to the brain or spine and to minimize secondary injury to the traumatized area. These technologies can include new medications, treatment protocols, monitoring protocols, equipment, and medical devices.

The Neurotrauma Center’s clinical research team includes physicians in all neuroscience specialties, neuroimaging specialists, research nurses, and regulatory experts. Patients who are treated at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Waddell Center for Multiple Sclerosis

Current research into Multiple Sclerosis focuses on the fundamental process of inflammation in the brain, how it starts, and how it can be slowed or stopped. Leading researchers in the field of neuroimmunology, neurosciences and neuroimaging have been recruited to the UC Waddell Center to participate in and initiate national clinical treatment trials that may someday solve the mysteries of this disease.

Our center supports dedicated physician-scientists who study various aspects of MS-related issues. We establish collaborations with physicians and scientists from Greater Cincinnati and throughout the world in the areas of immunology, neuro-virology, bioengineering, and MRI physics. Our philosophy is to adopt a “multimodality” approach to MS-related research, whereby similar questions can be addressed in parallel in animal models of neuroinflammation and in experiments performed on human cells and tissues, with MRI technology serving as a bridge between the two approaches.

With the substantial medical resources of the University of Cincinnati Medical Center, the UC Academic Health Center and the comprehensive therapy and rehabilitation programs at collaborating Drake Center and selected other providers, patients receive the best available care and benefit from the newest treatment technologies and therapies.

Our current clinical trials are carefully selected. Our goal is to select clinical trials that focus on novel, experimental therapies that have the potential to help patients who are inadequately treated by current, FDA-approved medications. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.

UC Gardner Center for Parkinson’s Disease and Movement Disorders

The UC James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders is a regional referral center within the UC Gardner Neuroscience Institute.

Physicians and scientists at the center are dedicated to improving care and working on research for patients with Parkinson’s disease and other movement disorders, such as Huntington’s disease, dystonia, and essential tremor. Since its inception, the center has received generous contributions from both public and private funders to advance care and accelerate the pace of research findings.

Our multidisciplinary team of care providers includes neurologists, neurosurgeons, nurse practitioners, neuropsychologists, nurse navigators, social workers, medical assistants, and research coordinators.  Our clinicians are skilled and experienced in the art and science of the accurate diagnosis and treatment of movement disorders. In fact, we diagnose and treat more patients with Parkinson’s disease and movement disorders than any other center in the Tri-state region.

Our team works together to determine the best course of treatment — which can include medication therapy, exercise regimens, voice therapy, and deep brain stimulation (DBS) surgery — and we consider all potential options in our effort to improve a patient’s quality of life. Our active research program has been focused on the study of neurodegenerative diseases and novel treatment developments for Parkinson’s disease and Huntington’s disease through local and North American-wide networks (e.g., Parkinson Study Group, Huntington Study Group, and NeuroNEXT).

If you are seeking care for yourself or a loved one with Parkinson’s disease or any other movement abnormality, we invite you to learn more about treatment of anxiety with CBD Oil,  and services, contact us with questions or call for an appointment.